breast cancer
Bio-Sourcing and Zerion Pharma receive 1.3m euros in funding for joint breast cancer project
January 14, 2026Research and Development Bio-Sourcing, Oncology, Zerion Pharma, breast cancer
Bio-Sourcing and Zerion Pharma have announced that their collaboration to develop an oral form of the monoclonal antibody trastuzumab for …
Biocartis announces breast cancer research collaboration with US Mayo Clinic
January 14, 2026Research and Development Biocartis, Mayo Clinic, Oncology, breast cancer
Biocartis has announced a research collaboration with Mayo Clinic in the US, aiming to develop an accelerated sample-to-answer test resulting …
Novartis receives SMC approval for early breast cancer treatment
November 11, 2025Research and Development Novartis, Scottish Medicines Consortium, breast cancer, nhs scotland
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval for use within NHS Scotland …
Micrima announces upcoming launch of new UK breast cancer assessment
October 3, 2025Research and Development Micrima, breast cancer, oncology
Breast cancer remains one of the leading health threats to women over 35 in the UK Micrima, a healthcare technology …
Pierre Fabre partners with Know Your Lemons Foundation for breast cancer awareness
October 2, 2025Medical Communications Education, Pierre Fabre, breast cancer
The campaign focuses on early detection and education Pierre Fabre Laboratories has announced a partnership with the Know Your Lemons …
Five Facts about Breast Cancer
October 2, 2025Medical Communications Breast Cancer Awareness Month, Five Facts, Oncology, breast cancer
1 There are striking inequities in breast cancer burden regarding the Human Development Index (HDI), the United Nation’s measure of …
Duke Street Bio receives FDA fast track designation for brain metastases treatment
July 8, 2025Medical Communications, Research and Development Duke Street Bio, Oncology, US Food and Drug Administration, brain metastases, breast cancer, fast track designation
Duke Street Bio, a biotech company based in London, UK, has announced that the US Food and Drug Administration (FDA) …
NICE recommendation for KORSERDU®▼ (elacestrant) marks ‘step-change’ in the treatment of ESR1-mutated metastatic breast cancer
December 19, 2024ESR1, Menari Group, NICE, breast cancer, drug
Elacestrant is the first tailored treatment for certain people with oestrogen receptor (ER)-positive HER2-negative locally advanced and metastatic breast cancer …
Merck shares data from phase 3 trial of Keytruda for TNBC treatment
May 29, 2024Medical Communications Merck, Oncology, breast cancer, clinical trial, keytruda
Merck, known as MSD outside of the US and Canada, has announced results from the phase 3 KEYNOTE-522 trial, which …
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
April 2, 2024Research and Development AstraZeneca, Daiichi Sankyo, FDA, Oncology, bla, breast cancer
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan (Dato-Dxd) has been accepted in …
Genentech shares positive results from phase 3 trial for breast cancer treatment
December 5, 2023Research and Development Genentech, Oncology, breast cancer, oncology
Genentech, a member of the Roche Group, has announced positive results from the phase 3 INAVO120 study, which assessed the …
FDA approves AstraZeneca’s Truqap plus Faslodex for breast cancer treatment
November 17, 2023Medical Communications AstraZeneca, FDA, Faslodex, Oncology, breast cancer
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Truqap (capivasertib) in combination with Faslodex (fullvestrant) …
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial
September 22, 2023Research and Development AstraZeneca, Daiichi Sankyo, Oncology, breast cancer, clinical trial
AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, which showed datopotamab deruxtecan (Dato-DXd) …
EC approves Menarini Group’s Orserdu for breast cancer treatment
September 21, 2023Medical Communications European Commission, Oncology, Orserdu, breast cancer
The Menarini Group and its subsidiary Stemline Therapeutics have announced that the European Commission (EC) has approved Orserdu (elacestrant) as …
Merck shares data from phase 3 trial for breast cancer treatment
August 1, 2023Research and Development MSD, Merck, Oncology, breast cancer, keytruda
Merck, also known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-756 …
